相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Proton pump inhibitors and clopidogrel: A difficult dilemma Response
Jolanta M. Siller-Matula et al.
AMERICAN HEART JOURNAL (2009)
A population-based study of the drug interaction between proton pump inhibitors and clopidogrel
David N. Juurlink et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2009)
Risk of Adverse Outcomes Associated With Concomitant Use of Clopidogrel and Proton Pump Inhibitors Following Acute Coronary Syndrome
P. Michael Ho et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38
Stephen D. Wiviott et al.
CIRCULATION (2008)
Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel
David S. Small et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
The biotransformation of prasugrel, a new thienopyridine prodrug, by the human carboxylesterases 1 and 2
Eric T. Williams et al.
DRUG METABOLISM AND DISPOSITION (2008)
Repeat oral dosing of prasugrel, a novel P2Y12 receptor inhibitor, results in cumulative and potent antiplatelet and antithrombotic activity in several animal species
Yoichi Niitsu et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2008)
Prasugrel, a new thienopyridine antiplatelet drug, weakly inhibits cytochrome P450 2B6 in humans
Nagy A. Farid et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel
David S. Small et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin
Martine Gilard et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2008)
The active metabolite of prasugrel effectively blocks the platelet P2Y(12) receptor and inhibits procoagulant and pro-inflammatory platelet responses
Heather M. Judge et al.
PLATELETS (2008)
Effect of Atorvastatin on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Healthy Subjects
Nagy A. Farid et al.
PHARMACOTHERAPY (2008)
Prasugrel achieves greater and faster P2Y(12) receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease
Lars Wallentin et al.
EUROPEAN HEART JOURNAL (2008)
Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention - The prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation-thrombolysis in myocardial infarction 44 trial
Stephen D. Wiviott et al.
CIRCULATION (2007)
Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel
J. T. Brandt et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)
Prasugrel versus clopidogrel in patients with acute coronary syndromes
Stephen D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel
Christopher D. Payne et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2007)
Greater inhibition of platelet aggregation and reduced response variability with prasugrel versus clopidogrel: An integrated analysis
Govinda J. Weerakkody et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS (2007)
Comparison of speed of onset of platelet inhibition after loading doses of clopidogrel versus prasugrel in healthy volunteers and correlation with responder status
Govinda J. Weerakkody et al.
AMERICAN JOURNAL OF CARDIOLOGY (2007)
The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite
A. Sugidachi et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)
The disposition of prasugrel, a novel thienopyridine, in humans
Nagy A. Farid et al.
DRUG METABOLISM AND DISPOSITION (2007)
Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently
N. A. Farid et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans
Joseph A. Jakubowski et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Dose-dependent inhibition of human platelet aggregation by prasugrel and its interaction with aspirin in healthy subjects
Joseph A. Jakubowski et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2007)
A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation
John T. Brandt et al.
AMERICAN HEART JOURNAL (2007)
Stereoselective metabolism of prasugrel in humans using a novel chiral liquid chromatography-tandem mass spectrometry method
Enaksha R. Wickremsinhe et al.
DRUG METABOLISM AND DISPOSITION (2007)
Antiplatelet agents aspirin and clopidogrel are hydrolyzed by distinct carboxylesterases, and clopidogrel is transesterificated in the presence of ethyl alcohol
Man Tang et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor:: A multiple-dose study in healthy humans
Nobuko Matsushima et al.
PLATELETS (2006)
ADP receptors: Inhibitory strategies for antiplatelet therapy
Marco Cattaneo
DRUG NEWS & PERSPECTIVES (2006)
Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor:: A single ascending dose study in healthy humans
Fumitoshi Asai et al.
PLATELETS (2006)
Platelet inhibition with prasugrel (CS-747) compared with clopidogrel in patients undergoing coronary stenting: the subset from the JUMBO study
V. L. Serebruany et al.
POSTGRADUATE MEDICAL JOURNAL (2006)
AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update - Endorsed by the National Heart, Lung, and Blood Institute
Sidney C. Smith et al.
CIRCULATION (2006)
Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease
T Jernberg et al.
EUROPEAN HEART JOURNAL (2006)
Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450
JLF Rehmel et al.
DRUG METABOLISM AND DISPOSITION (2006)
Angiographic and clinical outcomes in patients receiving low-molecular-weight heparin versus unfractionated heparin in ST-elevation myocardial infarction treated with fibrinolytics in the CLARITY-TIMI 28 trial
MS Sabatine et al.
CIRCULATION (2005)
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial
ZM Chen et al.
LANCET (2005)
Randomized comparison of Prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention -: Results of the joint utilization of medications to block platelets optimally (JUMBO)-TIMI 26 trial
SD Wiviott et al.
CIRCULATION (2005)
Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention
W Hochholzer et al.
CIRCULATION (2005)
Pharmacology of CS-747 (Prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity
Y Niitsu et al.
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2005)
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation
MS Sabatine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Clopidogrel-associated TTP - An update of pharmacovigilance efforts conducted by independent researchers, pharmaceutical suppliers, and the Food and Drug Administration
A Zakarija et al.
STROKE (2004)
Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance
WC Lau et al.
CIRCULATION (2004)
The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin
TA Clarke et al.
DRUG METABOLISM AND DISPOSITION (2003)
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention - A randomized controlled trial
SR Steinhubl et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2002)
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study
SR Mehta et al.
LANCET (2001)
The P2Y12 receptor as a therapeutic target in cardiovascular disease
RF Storey
PLATELETS (2001)
Clopidogrel - A review of its use in the prevention of atherothrombosis
B Jarvis et al.
DRUGS (2000)
The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties
A Sugidachi et al.
BRITISH JOURNAL OF PHARMACOLOGY (2000)
分享论文
